Evidence map›Paper›PMID 40555748›Full record

Trial reportNature medicine2025

Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.

Corby K Martin, Owen T Carmichael, Susan Carnell, Robert V Considine, David A Kareken, Ulrike Dydak, Richard D Mattes, David Scott, Sergey Shcherbinin, Hiroshi Nishiyama and 9 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Corby K MartinPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.ORCID http://orcid.org/0000-0002-8125-4015
Owen T CarmichaelPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.
Susan CarnellDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert V ConsidineDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-5033-3642
David A KarekenDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Ulrike DydakSchool of Health Sciences, Purdue University, West Lafayette, IN, USA.
Richard D MattesDepartment of Nutrition Science, Purdue University, West Lafayette, IN, USA.
David ScottClario, Inc., San Mateo, CA, USA.
Sergey ShcherbininEli Lilly and Company, Indianapolis, IN, USA.
Hiroshi NishiyamaEli Lilly and Company, Indianapolis, IN, USA.
Alastair KnightsEli Lilly and Company, Indianapolis, IN, USA.
Shweta UrvaEli Lilly and Company, Indianapolis, IN, USA.
Lukasz BiernatEli Lilly and Company, Indianapolis, IN, USA.
Edward PrattEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-4449-6231
Axel HauptEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-4502-0470
Mark MintunEli Lilly and Company, Indianapolis, IN, USA.
Diana Otero SvaldiEli Lilly and Company, Indianapolis, IN, USA.
Zvonko MilicevicEli Lilly and Company, Indianapolis, IN, USA.
Tamer CoskunEli Lilly and Company, Indianapolis, IN, USA. coskun_tamer@lilly.com.ORCID http://orcid.org/0000-0002-2481-133X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirzepatide induces weight reduction but the underlying mechanisms are unknown. This 6-week phase 1 study investigated early effects of tirzepatide on energy intake. Male and female adults without diabetes (n = 114) and a body mass index from 27 to 50 kg per m

Indexed as

Feeding BehaviorObesityOverweightAdultBody Mass IndexEnergy IntakeFemaleHumansLiraglutideMagnetic Resonance ImagingMaleMiddle AgedTirzepatideLiraglutideTirzepatide

Identifiers

PMID40555748
PMCPMC12443625

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.